LOGO Anti-cancer effect and structural characterization of endo-polysaccharide from cultivated mycelia of Inonotus obliquus Life Sciences 79 (2006) 72–80.

Slides:



Advertisements
Similar presentations
John A. Barrett Ph.D. Ziopharm Oncology, Boston MA 02129
Advertisements

The Journal of Immunology, 2013 March 27; 190: , IF=5.52
Cytokines, inflammation and cancer Alexandre Corthay Department of Immunology Oslo University Hospital Rikshospitalet and University of Oslo Oslo, Norway.
Quezada et al. J. Exp. Med. Vol. 205 No Presenters: Denise Rush Szymon Rus Harleen Saini.
Cancer immunology and immunotherapy. First an aside  Oncogenes and tumor suppressor genes.  Definitions anyone?  Oncogene –  Tumor suppressor gene.
Cancer Vaccines Medicines that belong to a class of substances known as biological response modifiers. Biological response modifiers stimulate or restore.
TUMOR IMMUNOLOGY Objectives
MONOCLONAL ANTIBODIES
Presented By: Lana Awad and Sebastian Lukjan. Motivation of research, why they did what they did…  Understand steps that cancer cells take to spread.
Cancer’s Trojan Horse Student ChE 391 October 3, 2002.
Insert Program or Hospital Logo Introduction Melanoma is notoriously resistant to chemotherapy. While surgical resection and adjuvant chemotherapy can.
Powerpoint Templates Page 1 Powerpoint Templates Gene therapy for melanoma By Mohammed razeeth.S.
Isosteviol derivatives induced apoptosis in Human lung cancer via targeting MEK/MAPK pathway: An in vitro and in vivo study Ahmed M Malki 1,,PhD Stephen.
1 Helicobacter pylori arginase inhibits nitric oxide production by eukaryotic cells: A strategy for bacterial survival PNAS November 20, 2001 vol. 98 no.
LOGO Anti-cancer effect and structural characterization of endo-polysaccharide from cultivated mycelia of Inonotus obliquus Life Sciences 79 (2006) 72–80.
IMIQUIMOD, AN IMMUNE-RESPONSE MODIFIER, IN THE TREATMENT OF TRANSITIONAL CELL CARCINOMA OF THE BLADDER Douglas Scherr, M.D. Department of Urology New York.
The Use of a Vesicular Delivery System in the Enhancement of Cisplatin Bioavailability Manal M. Alsaadi, Katharine C. Carter and Alexander B. Mullen Strathclyde.
BRG-1 in Cancer BRG-1 is an ATPase subunit of the SWI/SNF class of chromatin remodeling complexes It has been found mutated in a number of cancer cell.
Absence of Xeno-rejection and Xenoantibody Production in IL-7 KO Recipients After Xenoheart, but not after Xenoskin Transplantation. Shengqiao Li, Yuan.
LOGO Introduction  白樺茸是一種生長於白樺樹上的藥用真菌,其子實體 呈現類似炭的黑色塊狀型態主要是受到內部茶褐色色 素沈澱的影響﹔這種真菌的活性極強,會不斷吸取白樺 樹的養分,大約十至十五年之後就會把白樺樹的精華 吸收殆盡,使得白樺樹枯死。由於這種特殊的活性,
By: Sara Ibrahim Tel. # Cancer and The Immune System.
GROUP COMPONENT PROTEIN-DERIVED MACROPHAGE ACTIVATING FACTOR (GcMAF) STIMULATES MACROPHAGES THAT INDUCE HUMAN BREAST CANCER CELL APOPTOSIS M. Ruggiero,
M.Boothapandi Research Scholar Department of Zoology University of Madras Chennai Prof. R. Ramanibai Research Supervisor & Guide Department of Zoology.
Radiological and Medical Sciences Research Center KIRAMS, Seoul, Korea
Inducing and expanding regulatory T cell populations by foreign antigen Karsten Kretschmer NATURE IMMUNOLOGY 2005; 6:1219.
Fig. S1 Fig. S1. Experimental design of DSS-induced colitis (A) and AOM/DSS-induced colon carcinogenesis (B).
01/22/2010 – 7:45pmeSlide – P6617 – MedImmune 4 x 8 Poster Template Detection of a human anti-PDGFR  therapeutic antibody in a human GBM orthotopic rat.
第三章 Survivin siRNA nano particles are capable of inhibiting liver cancer cell growth both in vitro and in vivo Suoqin Tang,MD, Kuiyao Qu,MD, Yi Zhang,MD.
 Chemotherapy is a common strategy used to kill cancer cells.  However toxicity of chemotherapy drugs to normal cells limits their application.
Figure 1. Suppression of pro-inflammatory cytokine secretion on human intestinal epithelial Caco-2 cells CT-P13 and Remicade®. From: Comparable Immune.
Research, 2016, Vol. 4, No. 1, doi: /jfnr-4-1-6
Table 1. Scientific findings of previously published work on Graviola
A New Twist on Radiation Oncology: Low-Dose Irradiation Elicits Immunostimulatory Macrophages that Unlock Barriers to Tumor Immunotherapy  Michele De Palma,
Immunotherapy with Dendritic Cells Modified with Tumor-Associated Antigen Gene Demonstrates Enhanced Antitumor Effect Against Lung Cancer  Tao Jiang,
Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.
Volume 21, Issue 10, Pages (October 2013)
Metastasis-Promoting Immunity: When T Cells Turn to the Dark Side
Volume 16, Issue 6, Pages (June 2008)
Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.
Peritumoral injections of poly(I:C) induce type I IFN–dependent cytotoxic immunity and delay the growth of primary and transplanted Hgf-Cdk4R24C melanomas.
Host Immune Response to Infection and Cancer: Unexpected Commonalities
Volume 21, Issue 10, Pages (October 2013)
Volume 16, Issue 6, Pages (June 2008)
Inducible nitric oxide synthase (iNOS), early growth response protein 2 (Erg2) and podoplanin expression on in vitro-generated inflammatory alveolar macrophages.
Combination extract inhibits immune responses in vivo.
Figure 1. The activity of CD26/DPP4 in patient samples with lung adenocarcinoma. The measured activity is presented by ... Figure 1. The activity of CD26/DPP4.
Chie Kudo-Saito, Hiromi Shirako, Tadashi Takeuchi, Yutaka Kawakami 
Effect of YopM on the transcription of pro-inflammatory cytokines in HL60-derived macrophages after stimulation with LPS. HL60 cells differentiated into.
IFNα Induces MDSC Maturation and Loss of Suppressive Function
Table 1. Bioactive properties in Coriolus versicolor
PTX in combination with PLX397 induces antitumor T-cell response.
Molecular Therapy - Methods & Clinical Development
DPP-4 enhances M1 polarization and inhibits M2 polarization in macrophages in an ROS-dependent manner. DPP-4 enhances M1 polarization and inhibits M2 polarization.
NK Cells Fighting Cancer
CD49b+ cells from tumor-bearing mice are more prone to conversion into MDSCs compared with naive CD49b+ cells. CD49b+ cells from tumor-bearing mice are.
PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant p53 in vivo. PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant.
Wolbachia-induced responses of specific cell types.
Matriptase-2 inhibited breast tumor development in vivo.
Antitumor effects of celastrol in vitro and in vivo.
Prostaglandin E2 attenuates the host antitumor immunity to promote the HFD-induced HCC development. Prostaglandin E2 attenuates the host antitumor immunity.
DAC treatment alters immune cell composition and enhances cytokine production in the peritoneal lavage. DAC treatment alters immune cell composition and.
Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.
MGA271 exhibits potent in vivo antitumor activity toward tumor cell carcinoma xenografts. MGA271 exhibits potent in vivo antitumor activity toward tumor.
BMX inhibition suppresses the growth of CRPC cells in vitro and in vivo. BMX inhibition suppresses the growth of CRPC cells in vitro and in vivo. A, CWR22RV1.
Increased accumulation of pmel-1 T cells to tumor sites and enhanced antitumor immune response in mice receiving ACT combined with anti-PD-1 antibody treatment.
Proliferation of TA3-Ha and TA3-St cells in vitro and in vivo.
BCMab1 confers Fc-FcγR–dependent antitumor activity through both macrophages and NK cells. BCMab1 confers Fc-FcγR–dependent antitumor activity through.
Induction of PD-1 in B cells by TLR agonists and primary HCC-SN.
Immunological effects of anticancer therapy.
Knockdown of ROR1 increases the invasive potential of melanoma cells in vitro and in vivo. Knockdown of ROR1 increases the invasive potential of melanoma.
Presentation transcript:

LOGO Anti-cancer effect and structural characterization of endo-polysaccharide from cultivated mycelia of Inonotus obliquus Life Sciences 79 (2006) 72– /05/27

LOGO Results  Purification of endo-polysaccharide and sugar content determination.(Fig.2A&B) (Table 1) (Fig.3) (Fig.4A&B).(Fig.2A&B) (Table 1) (Fig.3) (Fig.4A&B)  Structural characterization of endo-polysaccharide. (Fig.5A&B) (Fig.5A&B)  Effect of endo-polysaccharide on the survival rate of mice implanted with cancer cells. (Fig.6A&B) (Table 2) (Fig.7) (Fig.8A&B)(Fig.6A&B) (Table 2) (Fig.7) (Fig.8A&B)  Cytotoxicity of endo-polysaccharide against cancer and normal cells. (Fig.9A&B)(Fig.9A&B)

LOGO Discussion  Kim et al. (2005) reported that the in vitro immuno-stimulating activity of water-soluble endo-polysaccharide isolated from I. obliquus mycelia is associated with functional stimulation of B-lymphocytes and macrophages.  The nitrite production of purified endo-polysaccharide markedly increased compared to crude endo-polysaccharide, indicating that the purified endo-polysaccharides enhance phagocytosis and nitric oxide production in macrophages, resulting in immuno-stimulating activity.  Thus, the anticancer effect of endo-polysaccharide in tumor- bearing mice is probably related to immuno-stimulation.

LOGO Discussion  The B16F10 murine melanoma cells which we used were a highly metastatic malignant neoplasm of melanocytes. The endo-polysaccharide suppressed the in vivo growth of melanoma cells in mice after both oral and intraperitoneal administration with intraperitoneal being more effective.  In most cases, intraperitoneal administration is more rapid and effective than oral (Bae et al., 2005).  However, it is unknown how orally administered substances are absorbed into the intestine. The anti-tumor action of endo- polysaccharide via oral administration is likely to involve multiple delivery processes (Carini et al., 2004).

LOGO Discussion  We therefore tested direct cytotoxicity and/or a proliferation effect of endo-polysaccharide in both tumor and normal cells. Most cancer cells were unaffected by endo-polysaccharide, except for the Hur7 and MCF-7 cell lines.  The endo-polysaccharide did not show any direct cytotoxic effect on melanoma cells at a dose of up to 200 μg/ml, and no cytotoxicity for normal cells.

LOGO Discussion  On the other hand, we found a proliferation effect for RAW264.7 macrophages at a high dose. The proliferation process might activate in vivo tumor growth.  Despite a marginal proliferation effect in vitro, we observed a strong endo-polysaccharide anti-tumor effect against B16F10 murine melanoma cells in vivo. This discrepancy suggests the existence of another action mode.

LOGO Discussion  Previously, we reported (Kim et al., 2005) that endo- polysaccharide can induce the macrophage enhanced mRNA expression of some inflammatory cytokines, including IL-1β, IL-6, iNOS and TNF-α. Administration of endo- polysaccharide enhanced the production of NO and tumoricidal cytokines by murine peritoneal macrophages at the initial phase of tumor development. The activated macrophages are believed to be involved in tumor cytotoxicity (Maeda et al., 1984).

LOGO Discussion  The polysaccharide linkage type is another important factor for anti-tumor or immuno-stimulating activity. Our endo- polysaccharide consists of α-linkages, according to 1 H NMR analysis. This structure is different from other known immuno- stimulating β-glucans (Usui et al., 1981; Mizuno et al., 1992).  Especially, the activity was considered to depend chiefly on the backbone structure of α-(1→3)-D-mannans. A detailed structural analysis is needed.

LOGO Conclusion  α-Linked fucoglucomannan isolated from cultivated mycelia of I. obliquus can inhibit tumor growth in vivo. The endo-polysaccharide-mediated inhibition of tumor growth is apparently caused by an induced humoral immunity of the host defense system rather than by a direct cytotoxic effect against tumor cells. The endo-polysaccharide from I. obliquus mycelia has a potential for clinical use in cancer prevention and treatment.